Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis

BACKGROUND: Pimavanserin, a selective 5-HT(2A) inverse agonist/antagonist, is the only treatment approved by the US Food and Drug Administration for hallucinations and delusions associated with Parkinson's disease (PD) psychosis. AIM: We aimed to evaluate motor- and cognition-related safety in...

Descripción completa

Detalles Bibliográficos
Autores principales: Abler, Victor, Brain, Cecilia, Ballard, Clive, Berrio, Ana, Coate, Bruce, Espay, Alberto J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580496/
https://www.ncbi.nlm.nih.gov/pubmed/36277907
http://dx.doi.org/10.3389/fneur.2022.919778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580496/
https://www.ncbi.nlm.nih.gov/pubmed/36277907
http://dx.doi.org/10.3389/fneur.2022.919778

Ejemplares similares